Monoclonal Antibody News and Research

RSS

Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

Researchers develop a rapid, specific, and accurate RT-qPCR-based method to detect and distinguish between Omicron sublineages

Researchers developed a novel, rapid and accurate qRT-PCR-based method to detect Omicron sublineages BA.1/BA.1.1 and BA.2 in patient samples.

18 Jul 2022

UC San Francisco neurologists focus on the hazards of abortion restrictions for women of reproductive age

UCSF Perspective Article Says New Ruling May Result in Increased Risk of Deaths, Disability.

14 Jul 2022

The potential of tixagevimab–cilgavimab for treating hospitalized COVID-19 patients

Scientists assessed the potential of tixagevimab–cilgavimab for treating hospitalized SARS-CoV-2 patients.

13 Jul 2022

Scientists explore antigenic imprinting in SARS-CoV-2

A recently published study compared monoclonal RBD antibody responses induced by SARS-CoV-2 Beta variant infections to antibodies induced by the ancestral virus in immunologically naive subjects.

12 Jul 2022

Monoclonal antibody treatment taken by hospitalized COVID-19 patients reduces mortality

A monoclonal antibody treatment taken by patients hospitalized with COVID-19 did not improve recovery time but did reduce deaths, according to a study published July 8 in The Lancet Respiratory Medicine.

8 Jul 2022

After 3 doses of COVID vaccine, most cancer patients retain detectable humoral immunity

In a recent study posted to the medRxiv* preprint server, researchers assessed the efficacy and durability of immune responses to the third dose of coronavirus disease 2019 (COVID-19) vaccines. They also assessed the efficacy of the fourth vaccine dose among severely immunocompromised patients with hematological malignancies.

7 Jul 2022

Novel COVID-19 antibody delivery approach advances to clinical trials

Under a Defense Advanced Research Projects Agency (DARPA) and Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) funded program, a novel COVID-19 antibody delivery approach has advanced to clinical trials.

7 Jul 2022

Vaccine generates antibodies that target SARS-CoV-2 spike protein regions shared among many coronaviruses

Could the SARS-CoV-2 vaccine reawaken previous antibody responses and point the way to a universal coronavirus vaccine? A new analysis of the antibody response to a COVID-19 vaccine suggests the immune system's history with other coronaviruses, including those behind the common cold, shapes the patient's response, according to a study published today in Cell Reports.

6 Jul 2022

Latest omicron subvariants are better at eluding vaccines and antibody treatments

The latest omicron subvariants-; including the BA.4 and BA.5 forms causing new surges in infections in the United States-; are even better at eluding vaccines and most antibody treatments than previous variants, finds a study by researchers at Columbia University Vagelos College of Physicians and Surgeons.

5 Jul 2022

Deep RNA sequencing with molecular dynamic simulations can detect neutralizing antibodies elicited by COVID-19 patients

In a new study, researchers reported on the non-ACE2 blocking neutralizing antibodies elicited in response to severe coronavirus disease 2019 using deep ribonucleic acid sequencing with >100 million reads per sample and molecular dynamic simulations.

5 Jul 2022

Casirivimab/imdevimab improve outcomes in early COVID-19

A new Viruses study determines the effect of casirivimab/imdevimab on IFN-1 and cytokines during SARS-CoV-2 infection.

29 Jun 2022

Immune particles from llama blood could offer protection against several COVID-19 variants

Mount Sinai-led researchers have shown that tiny, robust immune particles derived from the blood of a llama could provide strong protection against every COVID-19 variant, including Omicron, and 18 similar viruses including SARS-CoV-2 and SARS-CoV-1, which was responsible for the 2003 SARS outbreak.

29 Jun 2022

Potent antibody with a novel neutralization mechanism against SARS-CoV-2 variants

In a recent study posted to the bioRxiv* pre-print server, researchers in the United States described a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-neutralizing monoclonal antibody (mAb) SP1-77 that broadly neutralized its multiple variants of concern (VOCs).

28 Jun 2022

Low rates of severe COVID-19 found in patients treated with monoclonal antibodies during delta surge

A study of 10,775 high-risk adult patients during the COVID-19 delta variant surge in late 2021 finds that treatment with one of three anti-spike neutralizing monoclonal antibodies for mild to moderate symptoms led to low rates of severe disease, hospitalization, ICU admission and mortality, according to Mayo Clinic researchers.

28 Jun 2022

Cell-based assay highlights differences in antibody neutralizing capacity for SARS-CoV-2 variants

A recent study by scientists at Celentyx Ltd, the University of Birmingham, and the University of Warwick and posted to the bioRxiv* preprint server illustrated a cell-based severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein attachment assay.

28 Jun 2022

A cancer patient who had SARS-CoV-2 for over eight months

In a recent study posted to the medRxiv* pre-print server, researchers in Israel described the case of a severely immunocompromised cancer patient who developed a chronic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

28 Jun 2022

COVID-19 outcomes improved for SARDs patients through Omicron wave

In a recent study posted to the medRxiv* pre-print server, researchers investigated coronavirus disease 2019 (COVID-19) incidence and severity among systemic autoimmune rheumatic diseases (SARDs) patients in Massachusetts, United States (US), between March 1, 2020, and January 31, 2022.

22 Jun 2022

Real-world study shows Paxlovid associated with lower hospitalization rates

In a recent study posted to the medRxiv* pre-print server, researchers investigated the effectiveness of nirmatrelvir plus ritonavir in preventing hospitalizations among individuals aged 50 or older and vaccinated for coronavirus disease 2019 (COVID-19).

20 Jun 2022

Combination of three technologies makes potential treatment effective against aggressive brain tumor

A drug carrier able to reach the brain, bind to an aggressive type of tumor called glioblastoma multiforme, and release a chemotherapeutic agent has been tested for the first time by Brazilian researchers.

15 Jun 2022

Spirea raises £2.4M ($3M) to develop antibody drug conjugates in cancer

Funding will enable the development of Spirea’s pipeline of antibody drug conjugate therapeutics for the treatment of solid tumours.

From Spirea 14 Jun 2022

Monoclonal Antibody News and Research

Further Reading

Researchers develop a rapid, specific, and accurate RT-qPCR-based method to detect and distinguish between Omicron sublineages

UC San Francisco neurologists focus on the hazards of abortion restrictions for women of reproductive age

The potential of tixagevimab–cilgavimab for treating hospitalized COVID-19 patients

Scientists explore antigenic imprinting in SARS-CoV-2

Monoclonal antibody treatment taken by hospitalized COVID-19 patients reduces mortality

After 3 doses of COVID vaccine, most cancer patients retain detectable humoral immunity

Novel COVID-19 antibody delivery approach advances to clinical trials

Vaccine generates antibodies that target SARS-CoV-2 spike protein regions shared among many coronaviruses

Latest omicron subvariants are better at eluding vaccines and antibody treatments

Deep RNA sequencing with molecular dynamic simulations can detect neutralizing antibodies elicited by COVID-19 patients

Casirivimab/imdevimab improve outcomes in early COVID-19

Immune particles from llama blood could offer protection against several COVID-19 variants

Potent antibody with a novel neutralization mechanism against SARS-CoV-2 variants

Low rates of severe COVID-19 found in patients treated with monoclonal antibodies during delta surge

Cell-based assay highlights differences in antibody neutralizing capacity for SARS-CoV-2 variants

A cancer patient who had SARS-CoV-2 for over eight months

COVID-19 outcomes improved for SARDs patients through Omicron wave

Real-world study shows Paxlovid associated with lower hospitalization rates

Combination of three technologies makes potential treatment effective against aggressive brain tumor

Spirea raises £2.4M ($3M) to develop antibody drug conjugates in cancer

Immunology eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News